Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury.
Sponsor: London Health Sciences Centre Research Institute
Summary
Cognitive decline is increasingly recognized among patients receiving maintenance hemodialysis (HD). This can include trouble remembering, slower thinking or mentally feeling foggy. This research is being done to determine if a new medication (AV-001) can protect the brain from injury caused by hemodialysis by strengthening blood vessels in the brain and reducing inflammation. If successful, this research could lead to better protection for the brains of people undergoing regular dialysis, potentially reducing the risk of cognitive decline and stroke.
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Exploratory Study to Evaluate the Neuroprotective Effects of AV-001 on Hemodialysis-induced Brain Injury Via Cerebrovascular Stabilization in Chronic Hemodialysis Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-12-01
Completion Date
2027-12-31
Last Updated
2025-11-19
Healthy Volunteers
No
Conditions
Interventions
AV-001 or Placebo Injection
AV-001 or Placebo administered via IV bolus injection.
Locations (1)
London Health Sciences Centre
London, Ontario, Canada